Home Business Johnson & Johnson: fourth quarter earnings tripled. Covid vaccine sales: giant expects up to $ 3.5bn in 2022

Johnson & Johnson: fourth quarter earnings tripled. Covid vaccine sales: giant expects up to $ 3.5bn in 2022

by admin
  1. Home ››
  2. News >>
  3. World News ››


FACEBOOK
TWITTER
LINKEDIN

American pharmaceutical giant and Covid vaccine manufacturer Johnson & Johnson announced that it ended the fourth quarter of the year with unadjusted profits up to $ 4.74 billion, nearly tripled from $ 1.74 billion in the same period last year. .

Revenue also grew, up 10.8% year-on-year from $ 22.48 billion in the fourth quarter of 2020, mainly thanks to international sales of the Covid vaccine, amounting to $ 1.82 billion.

However, the turnover was less than the $ 25.29 billion expected by the consensus.

Adjusted eps came in at $ 2.13, better than the $ 2.12 per share expected by analysts.

In full 2021 Johnson & Johnson reported a turnover of $ 93.77 billion, up 13.6% year-on-year: the pharmaceutical division generated revenues of $ 52.08 billion, up 14.3 % every year. The medical equipment division grossed $ 27.06 billion in sales in 2021, up 17.9% year-on-year. The consumer products division saw revenue increase 4.1% to $ 14.63 billion.

J&J also announced that it expects an eps of between $ 10.40 and $ 10.60 this year, on revenues between $ 98.9 billion and $ 100.4 billion.

The giant also announced that its Covid vaccine will generate sales of between $ 3 billion and $ 3.5 billion in 2022.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy